Literature DB >> 25050776

Design and synthesis of potent macrocyclic HIV-1 protease inhibitors involving P1-P2 ligands.

Arun K Ghosh1, Gary E Schiltz, Linah N Rusere, Heather L Osswald, D Eric Walters, Masayuki Amano, Hiroaki Mitsuya.   

Abstract

A series of potent macrocyclic HIV-1 protease inhibitors have been designed and synthesized. The compounds incorporated 16- to 19-membered macrocyclic rings between a nelfinavir-like P2 ligand and a tyrosine side chain containing a hydroxyethylamine sulfonamide isostere. All cyclic inhibitors are more potent than their corresponding acyclic counterparts. Saturated derivatives showed slight reduction of potency compared to the respective unsaturated derivatives. Compound containing a 16-membered ring as the P1-P2 ligand showed the most potent enzyme inhibitory and antiviral activity.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25050776      PMCID: PMC4133278          DOI: 10.1039/c4ob00738g

Source DB:  PubMed          Journal:  Org Biomol Chem        ISSN: 1477-0520            Impact factor:   3.876


  23 in total

1.  Mechanism and activity of ruthenium olefin metathesis catalysts.

Authors:  M S Sanford; J A Love; R H Grubbs
Journal:  J Am Chem Soc       Date:  2001-07-11       Impact factor: 15.419

2.  Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance.

Authors:  Arun K Ghosh; Perali Ramu Sridhar; Sofiya Leshchenko; Azhar K Hussain; Jianfeng Li; Andrey Yu Kovalevsky; D Eric Walters; Joseph E Wedekind; Valerie Grum-Tokars; Debananda Das; Yasuhiro Koh; Kenji Maeda; Hiroyuki Gatanaga; Irene T Weber; Hiroaki Mitsuya
Journal:  J Med Chem       Date:  2006-08-24       Impact factor: 7.446

3.  Structure-based design: synthesis and biological evaluation of a series of novel cycloamide-derived HIV-1 protease inhibitors.

Authors:  Arun K Ghosh; Lisa M Swanson; Hanna Cho; Sofiya Leshchenko; Khaja Azhar Hussain; Stephanie Kay; D Eric Walters; Yasuhiro Koh; Hiroaki Mitsuya
Journal:  J Med Chem       Date:  2005-05-19       Impact factor: 7.446

4.  A simple, continuous fluorometric assay for HIV protease.

Authors:  M V Toth; G R Marshall
Journal:  Int J Pept Protein Res       Date:  1990-12

5.  Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease.

Authors:  S W Kaldor; V J Kalish; J F Davies; B V Shetty; J E Fritz; K Appelt; J A Burgess; K M Campanale; N Y Chirgadze; D K Clawson; B A Dressman; S D Hatch; D A Khalil; M B Kosa; P P Lubbehusen; M A Muesing; A K Patick; S H Reich; K S Su; J H Tatlock
Journal:  J Med Chem       Date:  1997-11-21       Impact factor: 7.446

6.  Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials.

Authors:  Ravindra Gupta; Andrew Hill; Anthony W Sawyer; Deenan Pillay
Journal:  Clin Infect Dis       Date:  2008-09-01       Impact factor: 9.079

7.  Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro.

Authors:  Yasuhiro Koh; Hirotomo Nakata; Kenji Maeda; Hiromi Ogata; Geoffrey Bilcer; Thippeswamy Devasamudram; John F Kincaid; Peter Boross; Yuan-Fang Wang; Yunfeng Tie; Patra Volarath; Laquasha Gaddis; Robert W Harrison; Irene T Weber; Arun K Ghosh; Hiroaki Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

8.  Novel cyclourethane-derived HIV protease inhibitors: a ring-closing olefin metathesis based strategy.

Authors:  Arun K Ghosh; Lisa M Swanson; Chunfeng Liu; Khaja Azhar Hussain; Hanna Cho; D Eric Walters; Louis Holland; Jim Buthod
Journal:  Bioorg Med Chem Lett       Date:  2002-08-05       Impact factor: 2.823

9.  Molecular analysis of the HIV-1 resistance development: enzymatic activities, crystal structures, and thermodynamics of nelfinavir-resistant HIV protease mutants.

Authors:  Milan Kozísek; Jenelle Bray; Pavlína Rezácová; Klára Sasková; Jirí Brynda; Jana Pokorná; Fabrizio Mammano; Lubomír Rulísek; Jan Konvalinka
Journal:  J Mol Biol       Date:  2007-10-03       Impact factor: 5.469

10.  Demonstration of sustained drug-resistant human immunodeficiency virus type 1 lineages circulating among treatment-naïve individuals.

Authors:  Stéphane Hué; Robert J Gifford; David Dunn; Esther Fernhill; Deenan Pillay
Journal:  J Virol       Date:  2009-01-21       Impact factor: 5.103

View more
  7 in total

Review 1.  Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS.

Authors:  Arun K Ghosh; Heather L Osswald; Gary Prato
Journal:  J Med Chem       Date:  2016-01-22       Impact factor: 7.446

2.  Design, synthesis, X-ray studies, and biological evaluation of novel macrocyclic HIV-1 protease inhibitors involving the P1'-P2' ligands.

Authors:  Arun K Ghosh; W Sean Fyvie; Margherita Brindisi; Melinda Steffey; Johnson Agniswamy; Yuan-Fang Wang; Manabu Aoki; Masayuki Amano; Irene T Weber; Hiroaki Mitsuya
Journal:  Bioorg Med Chem Lett       Date:  2017-09-06       Impact factor: 2.823

3.  Structure-based design, synthesis, X-ray studies, and biological evaluation of novel HIV-1 protease inhibitors containing isophthalamide-derived P2-ligands.

Authors:  Arun K Ghosh; Jun Takayama; Luke A Kassekert; Jean-Rene Ella-Menye; Sofiya Yashchuk; Johnson Agniswamy; Yuan-Fang Wang; Manabu Aoki; Masayuki Amano; Irene T Weber; Hiroaki Mitsuya
Journal:  Bioorg Med Chem Lett       Date:  2015-05-30       Impact factor: 2.823

4.  Design and Development of Highly Potent HIV-1 Protease Inhibitors with a Crown-Like Oxotricyclic Core as the P2-Ligand To Combat Multidrug-Resistant HIV Variants.

Authors:  Arun K Ghosh; Kalapala Venkateswara Rao; Prasanth R Nyalapatla; Heather L Osswald; Cuthbert D Martyr; Manabu Aoki; Hironori Hayashi; Johnson Agniswamy; Yuan-Fang Wang; Haydar Bulut; Debananda Das; Irene T Weber; Hiroaki Mitsuya
Journal:  J Med Chem       Date:  2017-04-18       Impact factor: 7.446

5.  Design of novel HIV-1 protease inhibitors incorporating isophthalamide-derived P2-P3 ligands: Synthesis, biological evaluation and X-ray structural studies of inhibitor-HIV-1 protease complex.

Authors:  Arun K Ghosh; Margherita Brindisi; Prasanth R Nyalapatla; Jun Takayama; Jean-Rene Ella-Menye; Sofiya Yashchuk; Johnson Agniswamy; Yuan-Fang Wang; Manabu Aoki; Masayuki Amano; Irene T Weber; Hiroaki Mitsuya
Journal:  Bioorg Med Chem       Date:  2017-04-09       Impact factor: 3.641

6.  Design, synthesis, and X-ray studies of potent HIV-1 protease inhibitors incorporating aminothiochromane and aminotetrahydronaphthalene carboxamide derivatives as the P2 ligands.

Authors:  Arun K Ghosh; Ravindra D Jadhav; Hannah Simpson; Satish Kovela; Heather Osswald; Johnson Agniswamy; Yuan-Fang Wang; Shin-Ichiro Hattori; Irene T Weber; Hiroaki Mitsuya
Journal:  Eur J Med Chem       Date:  2018-09-18       Impact factor: 6.514

7.  Study of the antimalarial properties of hydroxyethylamine derivatives using green fluorescent protein transformed Plasmodium berghei.

Authors:  Mariana Conceição Souza; Tatiana Almeida Padua; Natalia Domingos Torres; Maria Fernanda de Souza Costa; Victor Facchinetti; Claudia Regina Brandão Gomes; Marcus Vinícius Nora Souza; Maria das Graças Henriques
Journal:  Mem Inst Oswaldo Cruz       Date:  2015-05-26       Impact factor: 2.743

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.